Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06470841
PHASE2

CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML

Sponsor: Navy General Hospital, Beijing

View on ClinicalTrials.gov

Summary

The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.

Official title: CHG Regimen Combined With Venetoclax and Azacytidine in Newly Diagnosed Acute Myeloid Leukemia

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

85

Start Date

2024-09-20

Completion Date

2028-12

Last Updated

2024-08-22

Healthy Volunteers

No

Interventions

DRUG

CHG Combined With Venetoclax and Azacytidine

Patients were treated by CHG Combined With Venetoclax and Azacytidine: Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7; Homoharringtonine 1mg/m2 iv qd d1-14; Cytarabine 10mg/m2 subcutaneous injection q12h d1-14; G 250ug/m2 subcutaneous injection qd d0-14.

Locations (1)

Navy General Hospital

Beijing, Beijing Municipality, China